Condition: Advanced Solid Tumor · Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
This description comes directly from the study's public registry record.
Xingxing Liu · +86 18652105536 · liuxx2@hspharm.com
Always discuss trial participation with your own doctor first.
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05911464